PUBLISHED DATE : Jan 2023 | Pages : 189
Fill out your details & get your free sample
The Global Hepatocellular Carcinoma Treatment Market Share, Size, & Trends Analysis Report by
189 Pages
9 Tables
114 Charts
3 Regions
8 Countries
24 Companies
4 Market Segment
| Report Attribute | Details |
|---|---|
| Market Size - (2027) | USD 7.33 Billion |
| Market Size- (2021) | USD 2.80 Billion |
| CAGR (2021-2027) | 17.39% |
| Base Year | 2021 |
| Forecast Year | 2027 |
| Market Segments | Drug Class, Gender Type, Age Group, and Geography |
| Geographic Analysis | North America, Europe, APAC |
| Countries Covered | United States, France, Germany, Italy, UK, Spain, China, and Japan |
The global hepatocellular carcinoma treatment market size is expected to reach USD 7.3 billion by 2027, growing at a CAGR of 17.39% from 2022-2027. Hepatocellular carcinoma (HCC) is the most common form of liver cancer and accounts for ~90% of cases. HCC is particularly aggressive and has a poor survival rate (five-year survival <5%) and therefore remains a significant public health issue worldwide. In Asia and Africa, factors for development include Hepatitis B and C infection, aflatoxin exposure, liver cirrhosis, and hemochromatosis. In contrast, in developed countries, factors for developing HCC include diabetes, obesity, and non-alcoholic steatohepatitis (NASH). According to published studies, liver cancer is a leading cause of cancer death worldwide, accounting for more than 800,000 deaths and 900,000 new cases yearly.
Arizton estimates that the prevalence of hepatocellular carcinoma will be high in China, followed by the US and Japan in 2020. The increasing prevalence of HCC is driving the hepatocellular carcinoma treatment market growth. According to estimates, more than 1 million people will be affected with hepatocellular carcinoma annually by 2025.
Hepatocellular Carcinoma Therapeutics: Pipeline Scenario
The global hepatocellular carcinoma treatment market portfolio contains a total of 155+ assets in various development phases. Most industry-sponsored drugs in active clinical development for HCC are in the Phase II stage. Anti-PD-1 and PD-L1 monoclonal antibodies are dominating the Hepatocellular Carcinoma drug pipeline.
Hepatocellular Carcinoma Therapeutics: Clinical Trials Scenario
The clinical trial portfolio of the hepatocellular carcinoma treatment market contains 220+ trials in various development phases. Most industry-sponsored drugs in active clinical development for hepatocellular carcinoma are in the Phase II stage. The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for hepatocellular carcinoma have been in the early and mid-phases of development, with 55-60% of trials in Phase I-II and only 40% in Phase III-IV. The US has a substantial lead in the number of hepatocellular carcinoma clinical trials globally.
Increasing Adoption for Biological Therapies
Biological therapies such as immune-targeted therapies (Immunotherapies) are widely used to treat hepatocellular carcinoma. With Nivolumab being the biologic approved for hepatocellular carcinoma in 2017, there is a demand for therapies with novel MOAs. Many new classes of therapies are looking to enter the global hepatocellular carcinoma treatment market over the next few years. The biologics such as programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) make inroads into the hepatocellular carcinoma market owing to their better clinical profile.
Anticipated Launch of Emerging Drugs
A recent wave of biologic products prescribed for treating HCC is likely to create a lucrative opportunity for hepatocellular carcinoma (HCC) treatment market growth. Despite the plethora of therapies currently available to patients with hepatocellular carcinoma (HCC), there is still room for improvement within the treatment space. Arizton anticipates the launch of five new agents among the 8MM, including three programmed cell death 1 (PD-1) inhibitors (Camrelizumab, Tislelizumab, and Cemiplimab), one programmed cell death ligand 1 (PD-L1) inhibitor (Durvalumab) and one Lymphocyte-activation gene (LAG-3) inhibitor (Relatlimab). Launching these late-stage drugs will create an opportunity for the AD market growth.
Focus on Novel Drugs with Novel Mechanism
The therapeutic agents targeting PD-1 and PD-L1 have been proven to be very effective in HCC, some are already in the therapeutic armamentarium, and others are in development. Over the next five years, Arizton expects to see a surge of innovation emerging from the research and development pipeline and a range of technology-enabled transformations that will expand the evidence-basis for interventions and bring measurable improvements to outcomes.
Chemotherapeutic drugs are expected to dominate the global HCC therapeutics market among the drug class. However, the targeted therapies are expected to be the fastest-growing segment during the forecast period. Recently approved biologics such as Tecentriq (Atezolizumab) are expected to drive the global hepatocellular carcinoma treatment market from 2022-2027. The HCC industry has historically relied on chemotherapies that have been available for over a decade. But recent developments have led to research on novel mechanisms of action (MOAs) to combat the high numbers of patients experiencing treatment non-response. The hepatocellular carcinoma treatment market will experience significant growth due mainly to the launch of new drugs, most of which are expected to launch between 2023–2026, targeting the moderate-to-severe patient population. The biologics such as anti-PD-1 and PD-L1 inhibitors are making inroads into the HCC market owing to their better clinical profile.
Among the gender type, men were expected to account for a significant share of the global hepatocellular carcinoma treatment market based on gender type. This is because of more likely men predominance over women.
The global hepatocellular carcinoma treatment market based on age group is dominated by the 50 yrs & above age group segment. The disease can occur at any age, but HCC is most often diagnosed in adolescents and adults between 50 and 65.
The US dominates the global hepatocellular carcinoma treatment market by geography due to the healthcare affordability in the US, the knowledge and awareness amongst the people, and the technological advancement in this region. However, China is expected to grow faster with a high CAGR in the HCC drug market due to the rise in access and quality of healthcare, increased awareness about disease management, and rising healthcare expenditure in this region. Among 8MM, the US accounts for a significant market share of 48.07%, with a CAGR of 19.33% in the hepatocellular carcinoma treatment market.
The global hepatocellular carcinoma treatment market is dominated by many companies offering generic drugs and selective pharma/biotech companies offering patented/commercial drugs for treating hepatocellular carcinoma. The U.S. Food and Drug Administration (FDA) approved the Anti PD-1 monoclonal antibody Nivolumab (Opdivo) for treating HCC in 2017. Following this, the FDA approved Keytruda (pembrolizumab) in 2018 and Tecentriq (atezolizumab) in 2020 for treating HCC. Although generic products continue to capture significant hepatocellular carcinoma treatment market share, the arrival of biologics and other targeted therapies indicate a paradigm shift in this therapeutic space through the forecast period.
The hepatocellular carcinoma portfolio contains a total of 155+ assets in various development phases. The emerging therapeutics being developed for hepatocellular carcinoma include Camrelizumab, Tislelizumab, Cemiplimab, CS-1003, Relatlimab, and others. Launching these novel emerging drugs will shift the hepatocellular carcinoma treatment paradigm in the near future. With more than 155+ molecules in various stages of development, it is expected that new vendors are likely to enter the market with novel mechanisms of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating HCC.
The prominent players offering drugs in the global hepatocellular carcinoma treatment market includes Roche, Bayer, Merck & Co., Bristol-Myers Squibb, Exelixis Inc, Eli Lilly and Company, Innovent Biologics, AstraZeneca, BeiGene, Jiangsu HenGrui Medicine, and many others. These players are focused on R&D initiatives for developing technologically advanced and innovative HCC drugs and are also entering into collaborations to maintain their position in the market. These companies have adopted strategies such as collaborations & acquisitions, expansion of geographical footprint, investments in research & development, and manufacture of novel drugs to compete in the global HCC therapeutics market.
Key Milestones In The Hepatocellular Carcinoma Treatment Market :
Key Mergers & Acquisitions In The Hepatocellular Carcinoma Treatment Market:
REPORT COVERS
Frequently Asked Questions
How big is the hepatocellular carcinoma treatment market?
The global hepatocellular carcinoma treatment market size is expected to reach USD 7.3 billion by 2027.
What is the growth rate of the hepatocellular carcinoma treatment market?
The hepatocellular carcinoma treatment market is growing with a CAGR of 17.39% from 2022-2027.
Who are the key players in the global hepatocellular carcinoma treatment market
Merck & Co., Bayer, Roche, Eli Lilly and Company, Bristol-Myers Squibb, Exelixis Inc (Exelixis), Innovent Biologics Inc, Akeso, Inc, Jiangsu Hengrui Medicine Co Ltd, AstraZeneca Plc, BeiGene, and Sanofi SA are the key players in the global hepatocellular carcinoma treatment market.
Which region holds the largest global hepatocellular carcinoma treatment market share?
The US accounted for the highest global hepatocellular carcinoma treatment market share. However, China is expected to be the fastest-growing segment during the forecast period.
What are the latest trends in the hepatocellular carcinoma treatment market?
High investment in research & development and focus on T-cell therapies are the latest trends in the hepatocellular carcinoma treatment market.
The global hepatocellular carcinoma treatment market is expected to grow at a CAGR of approximately 17.39% from 2022 to 2027.
The following factors are likely to contribute to the growth of the global hepatocellular carcinoma treatment market during the forecast period:
Base Year: 2021
Forecast Year: 2022-2027
The report considers the present scenario of the hepatocellular carcinoma treatment market and its market dynamics for 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market.
Key Vendors
Other Prominent Vendors
Segmentation by Drug Class
Segmentation by Gender Type
Segmentation by Age Group
Segmentation by Geography
Exhibit 1: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF HCC IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 2: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN 8 MAJOR MARKETS (2018 – 2020)
Exhibit 3: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 4: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF HCC BY AGE GROUP IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 5: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN 8 MAJOR MARKETS (2018 – 2020)
Exhibit 6: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 7: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF HCC IN US (2018 – 2027)
Exhibit 8: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN US (2018 – 2020)
Exhibit 9: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN US (2021 – 2027)
Exhibit 10: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF HCC BY AGE GROUP IN US (2018 – 2027)
Exhibit 11: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN US (2018 – 2020)
Exhibit 12: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN US (2021 – 2027)
Exhibit 13: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF HCC IN CHINA (2018 – 2027)
Exhibit 14: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN CHINA (2018 – 2020)
Exhibit 15: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN CHINA (2021 – 2027)
Exhibit 16: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF HCC BY AGE GROUP IN CHINA (2018 – 2027)
Exhibit 17: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN CHINA (2018 – 2020)
Exhibit 18: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN CHINA (2021 – 2027)
Exhibit 19: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF HCC IN JAPAN (2018 – 2027)
Exhibit 20: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN JAPAN (2018 – 2020)
Exhibit 21: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN JAPAN (2021 – 2027)
Exhibit 22: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF HCC BY AGE GROUP IN JAPAN (2018 – 2027)
Exhibit 23: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN JAPAN (2018 – 2020)
Exhibit 24: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN JAPAN (2021 – 2027)
Exhibit 25: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF HCC IN GERMANY (2018 – 2027)
Exhibit 26: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN GERMANY (2018 – 2020)
Exhibit 27: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN GERMANY (2021 – 2027)
Exhibit 28: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF HCC BY AGE GROUP IN GERMANY (2018 – 2027)
Exhibit 29: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN GERMANY (2018 – 2020)
Exhibit 30: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN GERMANY (2021 – 2027)
Exhibit 31: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF HCC IN UK (2018 – 2027)
Exhibit 32: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN UK (2018 – 2020)
Exhibit 33: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN UK (2021 – 2027)
Exhibit 34: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF HCC BY AGE GROUP IN UK (2018 – 2027)
Exhibit 35: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN UK (2018 – 2020)
Exhibit 36: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN UK (2021 – 2027)
Exhibit 37: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF HCC IN FRANCE (2018 – 2027)
Exhibit 38: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN FRANCE (2018 – 2020)
Exhibit 39: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN FRANCE (2021 – 2027)
Exhibit 40: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF HCC BY AGE GROUP IN FRANCE (2018 – 2027)
Exhibit 41: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN FRANCE (2018 – 2020)
Exhibit 3: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN FRANCE (2021 – 2027)
Exhibit 42: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF HCC IN ITALY (2018 – 2027)
Exhibit 43: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN ITALY (2018 – 2020)
Exhibit 44: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN ITALY (2021 – 2027)
Exhibit 45: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF HCC BY AGE GROUP ITALY (2018 – 2027)
Exhibit 46: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN ITALY (2018 – 2020)
Exhibit 47: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN ITALY (2021 – 2027)
Exhibit 48: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF HCC IN SPAIN (2018 – 2027)
Exhibit 49: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN SPAIN (2018 – 2020)
Exhibit 50: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF HCC IN SPAIN (2021 – 2027)
Exhibit 51: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF HCC BY AGE GROUP IN SPAIN (2018 – 2027)
Exhibit 52: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN SPAIN (2018 – 2020)
Exhibit 53: COMPARATIVE ANALYSIS OF INCIDENCE OF HCC IN SPAIN (2021 – 2027)
Exhibit 54: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 55: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET SNAPSHOT IN 8 MAJOR MARKETS (2018 – 2020)
Exhibit 56: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY AGE GROUP IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 57: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY GENDER TYPE IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 58: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY DRUG CLASS IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 59: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET IN US (2021 – 2027)
Exhibit 60: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET SNAPSHOT IN US (2018 – 2020)
Exhibit 61: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY AGE GROUP IN US (2021 – 2027)
Exhibit 62: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY GENDER TYPE IN US (2021 – 2027)
Exhibit 63: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY DRUG CLASS IN US (2021 – 2027)
Exhibit 64: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET IN CHINA (2021 – 2027)
Exhibit 65: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET SNAPSHOT IN CHINA (2018 – 2020)
Exhibit 66: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY AGE GROUP IN CHINA (2021 – 2027)
Exhibit 67: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY GENDER TYPE IN CHINA (2021 – 2027)
Exhibit 68: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY DRUG CLASS IN CHINA (2021 – 2027)
Exhibit 69: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET IN JAPAN (2021 – 2027)
Exhibit 70: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET SNAPSHOT IN JAPAN (2018 – 2020)
Exhibit 71: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY AGE GROUP IN JAPAN (2021 – 2027)
Exhibit 72: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY GENDER TYPE IN JAPAN (2021 – 2027)
Exhibit 73: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY DRUG CLASS IN JAPAN (2021 – 2027)
Exhibit 74: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET IN GERMANY (2021 – 2027)
Exhibit 75: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET SNAPSHOT IN GERMANY (2018 – 2020)
Exhibit 76: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY AGE GROUP IN GERMANY (2021 – 2027)
Exhibit 77: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY GENDER TYPE IN GERMANY (2021 – 2027)
Exhibit 78: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY DRUG CLASS IN GERMANY (2021 – 2027)
Exhibit 79: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET IN UK (2021 – 2027)
Exhibit 80: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET SNAPSHOT IN UK (2018 – 2020)
Exhibit 81: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY AGE GROUP IN UK (2021 – 2027)
Exhibit 82: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY GENDER TYPE IN UK (2021 – 2027)
Exhibit 83: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY DRUG CLASS IN UK (2021 – 2027)
Exhibit 84: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET IN FRANCE (2021 – 2027)
Exhibit 85: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET SNAPSHOT IN FRANCE (2018 – 2020)
Exhibit 86: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY AGE GROUP IN FRANCE (2021 – 2027)
Exhibit 87: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY GENDER TYPE IN FRANCE (2021 – 2027)
Exhibit 88: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY DRUG CLASS IN FRANCE (2021 – 2027)
Exhibit 89: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET IN ITALY (2021 – 2027)
Exhibit 90: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET SNAPSHOT IN ITALY (2018 – 2020)
Exhibit 91: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY AGE GROUP IN ITALY (2021 – 2027)
Exhibit 92: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY GENDER TYPE IN ITALY (2021 – 2027)
Exhibit 93: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY DRUG CLASS IN ITALY (2021 – 2027)
Exhibit 94: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET IN SPAIN (2021 – 2027)
Exhibit 95: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET SNAPSHOT IN SPAIN (2018 – 2020)
Exhibit 96: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY AGE GROUP IN SPAIN (2021 – 2027)
Exhibit 97: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY GENDER TYPE IN SPAIN (2021 – 2027)
Exhibit 98: HISTORIC & PROJECTED REVENUE OF HCC THERAPEUTICS MARKET BY DRUG CLASS IN SPAIN (2021 – 2027)
Exhibit 99: HEPATOCELLULAR CARCINOMA MARKETED DRUGS – AN OVERVIEW
Exhibit 100: HEPATOCELLULAR CARCINOMA MARKETED DRUGS – SUMMARY
Exhibit 101: PIPELINE DRUGS OVERVIEW IN HCC THERAPEUTICS MARKET
Exhibit 102: HCC PIPELINE DRUGS OVERVIEW BY DISEASE TYPE
Exhibit 103: HCC PIPELINE DRUGS OVERVIEW BY DEVELOPMENT PHASE
Exhibit 104: HCC PIPELINE DRUGS OVERVIEW BY ROUTE OF ADMINISTRATION
Exhibit 105: HCC PIPELINE DRUGS OVERVIEW BY MECHANISM OF ACTION
Exhibit 106: HCC PIPELINE DRUGS OVERVIEW BY MOLECULE TYPE
Exhibit 107: HCC PIPELINE DRUGS OVERVIEW BY GEOGRAPHY TYPE
Exhibit 108: HCC CLINICAL TRIAL ANALYSIS SNAPSHOT
Exhibit 109: HCC CLINICAL TRIAL ANALYSIS SNAPSHOT BY RECRUITMENT STATUS
Exhibit 110: HCC CLINICAL TRIAL ANALYSIS SNAPSHOT BY PRODUCT TYPE
Exhibit 111: HCC CLINICAL TRIAL ANALYSIS SNAPSHOT BY ROUTE OF ADMINISTRATION
Exhibit 112: HCC CLINICAL TRIAL ANALYSIS SNAPSHOT BY MOLECULE TYPE
Exhibit 113: HCC CLINICAL TRIAL ANALYSIS SNAPSHOT BY GEOGRAPHY TYPE
Exhibit 114: COMPETITIVE ASSESSMENT OF HCC THERAPEUTICS MARKET
Tables
Table 1: KEY MARKET DRIVERS IN HCC THERAPEUTICS MARKET
Table 2: KEY MARKET CONSTRAINTS IN HCC THERAPEUTICS MARKET
Table 3: KEY MARKET TRENDS IN HCC THERAPEUTICS MARKET
Table 4: KEY TENTATIVE TIMELINE APPROVALS OF PIPELINE DRUGS IN HCC
Table 5: KEY REGULATORY DESIGNATIONS OF PIPELINE DRUGS IN HCC
Table 6: KEY MILESTONES IN HCC THERAPEUTICS MARKET
Table 7: KEY DEALS & COLLABORATIONS IN HCC THERAPEUTICS MARKET
Table 8: KEY INACTIVE/DISCONTINUED PRODUCTS IN HCC THERAPEUTICS MARKET
Table 9: UNMET NEEDS/STRATEGIC RECOMMENDATIONS IN HCC THERAPEUTICS MARKET
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
